

Revenue from Operation up by 16%

(3rd Quarter & 9 Months, FY 2023 Consolidated Results)

Mumbai, 1st February, 2023: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 3rd Quarter & 9 Months ended 31st December 2022.

Q3 FY 2023 performance highlights (compared to Q3 FY 2022)

- Revenue from operations at Rs. 972 cr. against Rs. 838 cr.; up 16%.
- EBITDA at Rs. 170 cr. against Rs. 240 cr.; EBITDA at 17% of revenue from operations.
- Adjusted EBITDA stands at Rs. 207 cr. against Rs. 240 cr.; Adjusted EBITDA at 21% of revenue from operations. This is after adjusting forex derivative loss of Rs. 37 cr. included in other expenses with forex gain in other income.
- Profit after tax at Rs. 135 cr. against Rs. 192 cr.; PAT at 14% of revenue from operations.

9 Months FY 2023 performance highlights (compared to 9 Months FY 2022)

- Revenue from operations at Rs. 2,861 cr. against Rs. 2,471 cr., up 16%.
- EBITDA at Rs. 588 cr. against Rs. 723 cr.; EBITDA at 21% of revenue from operations.
- Adjusted EBITDA stands at Rs. 631 cr. against Rs. 723 cr.; Adjusted EBITDA at 22% of revenue from operations. This is after adjusting forex derivative loss of Rs. 43 cr. included in other expenses with forex gain in other income.
- Profit after tax at Rs. 466 cr. against Rs. 561 cr., PAT at 16% of revenue from operations.

Branded Generic Business (FY 2023)

Total Branded Generic	Q3 Sale was Rs. 666 cr. (Rs. 620 cr.) up 8%. 9M Sale was Rs. 2,065 cr. (Rs. 1,739 cr.) up 19%.
India	Q3 Sales was Rs. 294 cr. (Rs. 260 cr.), up 13%. 9M Sales was Rs. 888 cr. (Rs. 737 cr.), up 20%. As per secondary market data of <u>IQVIA MAT December 2022</u> , Ajanta's growth was 15% versus IPM growth of 7%. Therapeutic growths are as below: <ol style="list-style-type: none"> a. 12% in Cardiology (segment growth of 7%), b. 14% in Ophthalmology (segment growth of 14%), c. 24% in Dermatology (segment growth of 4%) and d. 20% in Pain Management (segment growth of 12%).
Asia	Q3 FY 2023, Sale was Rs. 228 cr. (Rs. 194 cr.) up 17%. 9M FY 2023, Sale was Rs. 719 cr. (Rs. 551 cr.) up 31%.
Africa	Q3 FY 2023, Sale was Rs. 145 cr. (Rs. 166 cr.) down 13%. 9M FY 2023, Sale was Rs. 458 cr. (Rs. 451 cr.) up 2%.

US Generic Business (FY 2023)

USA	Q3 Sale was Rs. 266 cr. (Rs. 166 cr.) up 61%. 9M Sale was Rs. 631 cr. (Rs. 528 cr.) up 19%. In US, during 9M FY 2023, company received 1 ANDA final approval, 1 tentative approval and filed 4 ANDA with US FDA. Out of 43 final ANDA approvals, we have commercialized 39 products. We hold 4 tentative approvals and 22 ANDAs are awaiting US FDA approval.
------------	---

Africa Institution Business (FY 2023)

Africa Institution	Q3 Sale was Rs. 31 cr. (Rs. 36 cr.) down 15%. 9M Sale was Rs. 141 cr. (Rs. 156 cr.) down 10%.
---------------------------	--

Note: Figures in bracket are for corresponding year same period.

R&D

Q3 FY 2023, R&D expenses were Rs. 61 cr., (Q3 FY 2022 Rs. 51 cr.), 6% of revenue.

9M FY 2023, R&D expenses were Rs. 174 cr. (9M FY 2022 Rs. 145 cr.), 6% of revenue.

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centre is located in Mumbai. Company has 7 world class manufacturing facilities located in India.

For last 10 financial years, company has posted healthy performance with its Revenue from Operations growing at 15% CAGR and net profit at 23% CAGR.

Earnings Conference Call

The Company will host an Earnings Conference Call at 1600 hrs. IST (1830 hrs. SST/HKT, 1130 hrs. BST, 0530 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	February 1, 2023 at 1600 – 1700 hrs IST 1830 – 1930 hrs SST/HKT 1130 – 1230 hrs BST 0530 – 0630 hrs US ET
Dial-in Numbers	
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
Diamond pass link	Click here to register
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement

Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December 2022

₹ in Crore

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	971.77	938.10	837.91	2,860.80	2,470.70	3,340.99
Other income (Refer note 4 (a))	34.93	40.35	24.03	108.04	86.20	115.68
Total Income	1,006.70	978.45	861.94	2,968.84	2,556.90	3,456.67
Expenses						
Cost of materials consumed	246.01	205.40	201.05	646.46	562.38	779.34
Purchases of stock-in-trade	39.64	40.83	27.29	117.01	101.88	136.10
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(16.32)	13.52	(39.28)	46.03	(71.31)	(83.17)
Employee benefits expense	192.42	186.14	162.19	561.50	480.26	645.78
Finance costs	2.84	0.99	0.95	4.71	2.86	10.20
Depreciation and amortisation expense	33.30	32.70	31.72	97.78	94.14	125.30
Other expenses (Refer note 4 (b))	340.47	295.87	247.08	902.15	674.88	933.64
Total Expenses	838.36	775.45	631.00	2,375.64	1,845.09	2,547.19
Profit before tax	168.34	203.00	230.94	593.20	711.81	909.48
Tax Expense						
Current Tax	38.37	56.37	41.35	140.25	156.06	191.67
Deferred Tax	(4.54)	(9.97)	(2.19)	(12.78)	(5.72)	5.13
Net Profit for the period	134.51	156.60	191.78	465.73	561.47	712.68
Other Comprehensive Income (OCI)						
Items that will be reclassified subsequently to profit or loss	12.67	2.66	(1.59)	20.53	(7.53)	(8.33)
Income tax relating to items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Items that will not be reclassified subsequently to profit or loss	(0.45)	(1.05)	(0.49)	(1.35)	(1.48)	0.55
Income tax relating to items that will not be reclassified to profit or loss	0.16	0.36	0.17	0.47	0.52	(0.19)
Other Comprehensive Income for the year, net of tax	12.38	1.97	(1.91)	19.65	(8.49)	(7.97)
Total Comprehensive Income for the period	146.89	158.57	189.87	485.38	552.98	704.71
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.71	25.71	17.39	25.71	17.39	17.17
Other Equity						3,247.17
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	10.50	12.22	14.78	36.35	43.26	54.97
(b) Diluted - in ₹	10.50	12.22	14.77	36.35	43.26	54.96

Notes :

- The above consolidated unaudited financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 1 February 2023. The statutory auditors have expressed unmodified opinion on the results for the quarter and nine month period ended 31 December 2022. The review report has been filed with the stock exchange and is available on company website.
- The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- Pursuant to approval given by its shareholders, the Group has during the quarter ended June 2022, issued 4,27,08,385 equity shares of ₹ 2 each as fully paid-up bonus equity shares in the ratio of 1 (one) equity share for every 2 (Two) existing equity share. Accordingly, the earnings per share has been adjusted for previous periods and presented in accordance with Ind AS 33, Earnings Per Share.
- Foreign exchange gain and loss :
 - Other income includes foreign exchange gain from derivative instrument of ₹ 7.07 Crore in quarter ended 31 December 2021, ₹ 24.74 Crore in nine month ended 31 December 2021 and ₹ 17.09 crore in the year ended 31 March 2022. Other income also includes foreign exchange gain of ₹ 27.21 Crore in quarter ended 31 December 2022, ₹ 32.96 Crore in quarter ended 30 September 2022, ₹ 4.22 Crore in quarter ended 31 December 2021, ₹ 87.78 Crore in nine months ended 31 December 2022, ₹ 24.49 Crore in nine month ended 31 December 2021 and ₹ 56.37 crore in the year ended 31 March 2022.
 - Other expense includes foreign exchange loss from derivative instrument of ₹ 36.99 Crore in quarter ended 31 December 2022, ₹ 3.90 Crore in quarter ended 30 September 2022 and ₹ 43.34 Crore in nine month ended 31 December 2022.
- The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

SREEJA
 RAJASEKHA
 RAN
 MARAR
 Digitally signed
 by SREEJA
 RAJASEKHARAN
 MARAR
 Date: 2023.02.01
 15:05:35 +05'30'

Mumbai, 1 February 2023

 By order of the Board
 For Ajanta Pharma Ltd.

YOGESH
 MANNAL
 AL
 Digitally signed by
 YOGESH
 MANNAL
 AGRAWAL
 Date: 2023.02.01
 14:17:51 +05'30'

 Yogesh M. Agrawal
 Managing Director

Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December 2022

₹ in Crore

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	874.89	837.23	808.58	2,562.41	2,375.01	3,140.64
Other income (Refer note 4 (a))	30.51	78.37	27.90	144.30	111.31	139.73
Total Income	905.40	915.60	836.48	2,706.71	2,486.32	3,280.37
Expenses						
Cost of materials consumed	246.01	205.41	198.61	646.47	556.03	773.04
Purchases of stock-in-trade	37.48	38.91	28.35	109.82	86.99	116.12
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(46.15)	(1.90)	(22.38)	(15.96)	(11.33)	(56.60)
Employee benefits expense	175.53	170.90	147.90	513.35	439.76	585.87
Finance costs	2.68	0.71	0.70	4.02	1.94	9.12
Depreciation and amortisation expense	32.29	31.80	30.71	94.84	90.87	120.96
Other expenses (Refer note 4 (b))	302.61	263.18	218.23	802.28	599.82	831.32
Total Expenses	750.45	709.01	602.12	2,154.82	1,764.08	2,379.83
Profit before tax	154.95	206.59	234.36	551.89	722.24	900.54
Tax Expense						
Current Tax	17.53	45.52	32.99	104.86	124.22	171.17
Deferred Tax	13.46	(6.11)	6.66	5.52	13.00	9.51
Net Profit for the period	123.96	167.18	194.71	441.51	585.02	719.86
Other Comprehensive Income (OCI)						
Items that will not be reclassified subsequently to profit or loss	(0.45)	(1.05)	(0.49)	(1.35)	(1.48)	0.55
Income tax relating to items that will not be reclassified to profit or loss	0.16	0.36	0.17	0.47	0.52	(0.19)
Other Comprehensive Income for the year, net of tax	(0.29)	(0.69)	(0.32)	(0.88)	(0.96)	0.36
Total Comprehensive Income for the period	123.67	166.49	194.39	440.63	584.06	720.22
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.71	25.71	17.39	25.71	17.39	17.17
Other Equity						3,152.01
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	9.67	13.05	15.00	34.46	45.07	55.52
(b) Diluted - in ₹	9.67	13.05	15.00	34.46	45.07	55.52

Notes :

1. The above standalone unaudited results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 1 February 2023. The statutory auditors have expressed unmodified opinion on the results for the quarter and nine month period ended 31 December 2022. The review report has been filed with the stock exchange and is available on company website.

2. Other income includes :

	Quarter ended			Nine months ended		Year ended
	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
Dividend from subsidiaries (₹ in Crore)	-	35.14	-	35.14	22.33	22.33

3. Pursuant to approval given by its shareholders, the Company has during the quarter ended June 2022, issued 4,27,08,385 equity shares of ₹ 2 each as fully paid-up bonus equity shares in the ratio of 1 (one) equity share for every 2 (Two) existing equity share. Accordingly, the earnings per share has been adjusted for previous periods and presented in accordance with Ind AS 33, Earnings Per Share.

4. Foreign exchange gain and loss :

(a) Other income includes foreign exchange gain from derivative instrument of ₹ 7.07 Crore in quarter ended 31 December 2021, ₹ 24.74 Crore in nine month ended 31 December 2021 and ₹ 17.09 crore in the year ended 31 March 2022. Other income also includes foreign exchange gain of ₹ 22.91 Crore in quarter ended 31 December 2022, ₹ 36.00 Crore in quarter ended 30 September 2022, ₹ 8.27 Crore in quarter ended 31 December 2021, ₹ 92.26 Crore in nine months ended 31 December 2022, ₹ 28.02 Crore in nine month ended 31 December 2021 and ₹ 58.85 crore in the year ended 31 March 2022.

(b) Other expense includes foreign exchange loss from derivative instrument of ₹ 36.99 Crore in quarter ended 31 December 2022, ₹ 3.90 Crore in quarter ended 30 September 2022 and ₹ 43.34 Crore in nine month ended 31 December 2022.

5. The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

6. The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

Digitally signed by
SREEJA
RAJASEKHA
RAN MARAR
 Date: 2023.02.01
 15:07:44 +05'30'

Mumbai, 1 February 2023

 By order of the Board
 For Ajanta Pharma Ltd.

YOGESH MANNAL
 AL
 AGRAWAL
Digitally signed by YOGESH MANNAL AGRAWAL
 DN: cn=2023.02.01
 AGRAWAL 14:17:48 +05'30'

Yogesh M. Agrawal
 Managing Director